The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study
Open accessAbstract
Purpose: Adjuvant chemotherapy, especially with anthracyclines, is known to cause acute and chronic cardiotoxicity in breast cancer patients. We studied the cardiac effects of chemotherapy in a population-based sample of breast cancer patients aged ≥ 65 years with long-term follow-up. Patients and Methods: In the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, we analyzed treatments and outcomes among women ≥ 65 years of age who were diagnosed with stage I to III breast cancer from January 1, 1992 to December 31, 1999. Propensity scores were used to control for baseline heart disease (HD) and other known predictors of chemotherapy, and Cox proportional hazards models were used to estimate the risk of cardiomyopathy (CM), congestive heart failure (CHF), and HD after chemotherapy. Results: Of 31,748 women with stage I to III breast cancer, 5,575 (18%) received chemotherapy. Chemotherapy was associated with younger age, fewer comorbidities, hormone receptor negativity, multiple primary tumors, and advanced disease. Patients who received chemotherapy were less likely than other patients to have pre-existing HD (45% v 55%, respectively; P < .001). The hazard ratios for CM, CHF, and HD for patients treated with doxorubicin (DOX) compared with patients who received no chemotherapy were 2.48 (95% CI, 2.10 to 2.93), 1.38 (95% CI, 1.25 to 1.52), and 1.35 (95% CI, 1.26 to 1.44), respectively. The relative risk of cardiotoxicity among patients who received DOX compared with untreated patients remained elevated 5 years after diagnosis. Conclusion: When baseline HD was taken into account, chemotherapy, especially with anthracyclines, was associated with a substantially increased risk of CM. As the number of long-term survivors grows, identifying and minimizing the late effects of treatment will become increasingly important.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Estimating Causal Effects from Large Data Sets Using Propensity Scores
Rubin, D. B. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-8_part_2-199710151-00064 · Cited by 2,877
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Gewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A., & Albain, K. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912303412706 · Cited by 2,174
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
Development of a comorbidity index using physician claims data
Klabunde, C. N., Potosky, A. L., Legler, J. M., & Warren, J. L. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00256-0 · Cited by 1,845
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · PubMed · doi:10.1097/01.mlr.0000020942.47004.03 · Cited by 1,714
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470120074036 · Cited by 989
Comorbidity and functional status are independent in older cancer patients.
Extermann, M., Overcash, J., Lyman, G. H., Parr, J., & Balducci, L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1582 · Cited by 984
Effect of Age and Comorbidity in Postmenopausal Breast Cancer Patients Aged 55 Years and Older
Yancik, R. (2001) · JAMA · doi:10.1001/jama.285.7.885 · Cited by 896
Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · Medical Care · doi:10.1097/00005650-200208001-00002 · Cited by 772
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
LEGHA, S. S., BENJAMIN, R. S., MACKAY, B., EWER, M., WALLACE, S., VALDIVIESO, M., RASMUSSEN, S. L., BLUMENSCHEIN, G. R., & FREIREICH, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 763
Anthracycline-Induced Cardiotoxicity
Shan, K., Lincoff, A. M., & Young, J. B. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00008 · Cited by 749
Side Effects of Adjuvant Treatment of Breast Cancer
Shapiro, C. L., & Recht, A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442607 · Cited by 724
Anthrazykline in der Krebstherapie: Ein Überblick
Hortobágyi, G. N. (1997) · Drugs · doi:10.2165/00003495-199700544-00003 · Cited by 678
Levine, M. N., Bramwell, V. H., Pritchard, K. I., Norris, B. D., Shepherd, L. E., Abu-Zahra, H., Findlay, B., Warr, D., Bowman, D., Myles, J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2651 · Cited by 617
Agostino, R. B. D. (1998) · Cited by 497
Krischer, J. P., Epstein, S., Cuthbertson, D. D., Goorin, A. M., Epstein, M. L., & Lipshultz, S. E. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1544 · Cited by 476
Recht, A., Come, S. E., Henderson, I. C., Gelman, R. S., Silver, B., Hayes, D. F., Shulman, L. N., & Harris, J. R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342102 · Cited by 436
Adjuvant Chemotherapy in Older and Younger Women With Lymph Node–Positive Breast Cancer
Muss, H. B. (2005) · JAMA · doi:10.1001/jama.293.9.1073 · Cited by 418
Utility of the SEER-Medicare Data to Identify Chemotherapy Use
Warren, J. L., Harlan, L. C., Fahey, A., Virnig, B. A., Freeman, J. L., Klabunde, C. N., Cooper, G. S., & Knopf, K. B. (2002) · Medical Care · doi:10.1097/00005650-200208001-00008 · Cited by 404
Epidemiology of anthracycline cardiotoxicity in children and adults.
Ma, G., & Se, L. (1998) · PubMed · Cited by 341
Early anthracycline cardiotoxicity
Bristow, M. R., Thompson, P. D., Martin, R. P., Mason, J. W., Billingham, M. E., & Harrison, D. C. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90802-1 · Cited by 334
Differential Prognostic Impact of Comorbidity
Read, W. L., Tierney, R. M., Page, N. C., Costas, I., Govindan, R., Spitznagel, E. L. J., & Piccirillo, J. F. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.040 · Cited by 323
Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin.
Zhou, S., Starkov, A. A., Froberg, M. K., Leino, R. L., & Wallace, K. B. (2001) · PubMed · Cited by 314
Racial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer
Hershman, D., McBride, R., Jacobson, J. S., Lamerato, L., Roberts, K., Grann, V. R., & Neugut, A. I. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.633 · Cited by 308
Self-citationCrivellari, D., Bonetti, M., Castiglione-Gertsch, M., Gelber, R. D., Rudenstam, C.-M., Thürlimann, B., Price, K. N., Coates, A. S., Hürny, C., Bernhard, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1412 · Cited by 291
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
Ryberg, M., Nielsen, D., Skovsgaard, T., Hansen, J., Jensen, B. V., & Dombernowsky, P. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3502 · Cited by 289
Mandelblatt, J. S., Hadley, J., Kerner, J. F., Schulman, K. A., Gold, K., Dunmore-Griffith, J., Edge, S., Guadagnoli, E., Lynch, J. J., Meropol, N. J., et al. (2000) · Cancer · doi:10.1002/1097-0142(20000801)89:3<561::aid-cncr11>3.0.co;2-a · Cited by 277
Cancer Treatment and Age: Patient Perspectives
Newcomb, P. A., & Carbone, P. P. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.19.1580 · Cited by 254
Clinical spectrum of anthracycline antibiotic cardiotoxicity.
Bristow, M. R., Billingham, M. E., Mason, J. W., & Daniels, J. R. (1978) · PubMed · Cited by 250
Adriamycin cardiotoxicity: a survey of 1273 patients.
Praga, C., Beretta, G., Pl, V., Gr, L., Pollini, C., Bonadonna, G., Canetta, R. M., Castellani, R., Villa, E., Cg, G., et al. (1979) · PubMed · Cited by 248
Du, X. L., Osborne, C., & Goodwin, J. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.05.088 · Cited by 238
The cardiotoxicity of anticancer agents.
Hoff, V., Rozencweig, M., & Piccart, M. J. (1982) · PubMed · Cited by 202
What Threshold for Adjuvant Therapy in Older Breast Cancer Patients?
Extermann, M., Balducci, L., & Lyman, G. H. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1709 · Cited by 199
Zambetti, M., Moliterni, A., Materazzo, C., Stefanelli, M., Cipriani, S., Valagussa, P., Bonadonna, G., & Gianni, L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.37 · Cited by 186
Patterns of Use of Chemotherapy for Breast Cancer in Older Women: Findings From Medicare Claims Data
Du, X., & Goodwin, J. S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1455 · Cited by 172
Acute arrhythmogenicity of doxorubicin administration
Steinberg, J. S., Cohen, A. J., Wasserman, A. G., Cohen, P., & Ross, A. M. (1987) · Cancer · doi:10.1002/1097-0142(19870915)60:6<1213::aid-cncr2820600609>3.0.co;2-v · Cited by 171
The Effect of Age and Comorbidity in the Treatment of Elderly Women With Nonmetastatic Breast Cancer
Newschaffer, C. J. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.1.85 · Cited by 165
Information on Radiation Treatment in Patients with Breast Cancer
Du, X. L., Freeman, J. L., & Goodwin, J. S. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00011-6 · Cited by 153
Doxorubicin-induced cardiomyopathy
(1984) · Reactions Weekly · doi:10.1007/bf03273255 · Cited by 139
The Effect of Age on the Care of Women With Breast Cancer in Community Hospitals
Chu, J. Y., Diehr, P. H., Feigl, P., Glaefke, G., Begg, C. B., Glicksman, A. S., & Ford, L. G. (1987) · Journal of Gerontology · doi:10.1093/geronj/42.2.185 · Cited by 131
Perez, E. A., Suman, V. J., Davidson, N. E., Kaufman, P. A., Martino, S., Dakhil, S. R., Ingle, J. N., Rodeheffer, R. J., Gersh, B. J., & Jaffe, A. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.516 · Cited by 131
Adjuvant Therapy for Breast Cancer: Practice Patterns of Community Physicians
Harlan, L. C., Abrams, J. S., Warren, J. L., Clegg, L., Stevens, J. L., & Ballard-Barbash, R. R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.052 · Cited by 119
Variation in staging and treatment of local and regional breast cancer in the elderly
Hillner, B. E., Penberthy, L., Desch, C. E., McDonald, M. K., Smith, T. J., & Retchin, S. M. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01806004 · Cited by 107
Fumoleau, P., Kerbrat, P., Romestaing, P., Fargeot, P., Bremond, A. G., Namer, M., Schraub, S., Goudier, M.-J., Mihura, J., Monnier, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.148 · Cited by 105
Du, X. L., Key, C. R., Osborne, C., Mahnken, J. D., & Goodwin, J. S. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-2-200301210-00009 · Cited by 101
Gemcitabine and radiation therapy for non-small cell lung cancer.
Vokes, E. E., Gregor, A., & Turrisi, A. T. (1998) · PubMed · Cited by 73
Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy.
Hrushesky, W. J. M., Fader, D. J., Berestka, J. S., Sommer, M. A., Hayes, J., & Cope, F. O. (1991) · Circulation · doi:10.1161/01.cir.84.2.697 · Cited by 36
D’Agostino (1998) · doi:10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b
Cited by
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N., Dent, S., Douglas, P. S., Durand, J.-B., Ewer, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5400 · Cited by 1,290
Metadata
- Authors
- Doyle, J. J., Neugut, A. I., Jacobson, J. S., Grann, V. R., & Hershman, D. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-12-01
- Volume
- 23
- Issue
- 34
- Pages
- 8597-8605
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2005849136
- Cited by
- 335
- References
- 54
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.